|
1
|
Bischoff CJ and Clark PE: Bladder cancer.
Curr Opin Oncol. 21:272–277. 2009. View Article : Google Scholar
|
|
2
|
Schenk-Braat EA and Bangma CH:
Immunotherapy for superficial bladder cancer. Cancer Immunol
Immunother. 54:414–423. 2005. View Article : Google Scholar
|
|
3
|
Shen Z, Shen T, Wientjes MG, O’Donnell MA
and Au JL: Intravesical treatments of bladder cancer: review. Pharm
Res. 25:1500–1510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sekiya K and Okuda H: Selective inhibition
of platelet lipoxygenase by baicalein. Biochem Biophys Res Commun.
105:1090–1095. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pidgeon GP, Kandouz M, Meram A and Honn
KV: Mechanisms controlling cell cycle arrest and induction of
apoptosis after 12-lipoxygenase inhibition in prostate cancer
cells. Cancer Res. 62:2721–2727. 2002.PubMed/NCBI
|
|
6
|
Wong BC, Wang WP, Cho CH, Fan XM, Lin MC,
Kung HF and Lam SK: 12-Lipoxygenase inhibition induced apoptosis in
human gastric cancer cells. Carcinogenesis. 22:1349–1354. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen SF, Hsu CW, Huang WH and Wang JY:
Post-injury baicalein improves histological and functional outcomes
and reduces inflammatory cytokines after experimental traumatic
brain injury. Br J Pharmacol. 155:1279–1296. 2008. View Article : Google Scholar
|
|
8
|
Boyle SP, Doolan PJ, Andrews CE and Reid
RG: Evaluation of quality control strategies in Scutellaria
herbal medicines. J Pharm Biomed Anal. 54:951–957. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He XL, Wang YH, Gao M, Li XX, Zhang TT and
Du GH: Baicalein protects rat brain mitochondria against chronic
cerebral hypoperfusion-induced oxidative damage. Brain Res.
1249:212–221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Ling Y, Chen Y, et al: Flavonoid
baicalein suppresses adhesion, migration and invasion of MDA-MB-231
human breast cancer cells. Cancer Lett. 297:42–48. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taniguchi H, Yoshida T, Horinaka M, et al:
Baicalein overcomes tumor necrosis factor-related
apoptosis-inducing ligand resistance via two different
cell-specific pathways in cancer cells but not in normal cells.
Cancer Res. 68:8918–8927. 2008. View Article : Google Scholar
|
|
12
|
Chen CH, Huang LL, Huang CC, Lin CC, Lee Y
and Lu FJ: Baicalein, a novel apoptotic agent for hepatoma cell
lines: a potential medicine for hepatoma. Nutr Cancer. 38:287–295.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma Z, Otsuyama K, Liu S, et al: Baicalein,
a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang
(HLJDT), leads to suppression of proliferation and induction of
apoptosis in human myeloma cells. Blood. 105:3312–3318.
2005.PubMed/NCBI
|
|
14
|
Carnero A: The PKB/AKT pathway in cancer.
Curr Pharm Des. 16:34–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Czabotar PE and Lessene G: Bcl-2 family
proteins as therapeutic targets. Curr Pharm Des. 16:3132–3148.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kirkin V, Joos S and Zörnig M: The role of
Bcl-2 family members in tumorigenesis. Biochim Biophys Acta.
1644:229–249. 2004. View Article : Google Scholar
|
|
17
|
Malaguarnera L: Implications of apoptosis
regulators in tumorigenesis. Cancer Metastasis Rev. 23:367–387.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsujimoto Y and Shimizu S: Role of the
mitochondrial membrane permeability transition in cell death.
Apoptosis. 12:835–840. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goswami A, Ranganathan P and Rangnekar VM:
The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective
therapeutic target. Cancer Res. 66:2889–2892. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen M, Gu J, Delclos GL, Killary AM, et
al: Genetic variations of the PI3K-AKT-mTOR pathway and clinical
outcome in muscle invasive and metastatic bladder cancer patients.
Carcinogenesis. 31:1387–1391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hartmann W, Küchler J, Koch A, et al:
Activation of phosphatidylinositol-3′-kinase/AKT signaling is
essential in hepatoblastoma survival. Clin Cancer Res.
15:4538–4545. 2009.
|
|
24
|
Danial NN: BCL-2 family proteins: critical
checkpoints of apoptotic cell death. Clin Cancer Res. 13:7254–7263.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J, Liu X, Bhalla K, et al: Prevention
of apoptosis by Bcl-2: Release of cytochrome c from mitochondria
blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Skommer J, Brittain T and Raychaudhuri S:
Bcl-2 inhibits apoptosis by increasing the time-to-death and
intrinsic cell-to-cell variations in the mitochondrial pathway of
cell death. Apoptosis. 15:1223–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT
and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma
cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res
Commun. 390:642–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reagan-Shaw S, Nihal M, Ahsan H, Mukhtar H
and Ahmad N: Combination of vitamin E and selenium causes an
induction of apoptosis of human prostate cancer cells by enhancing
Bax/Bcl-2 ratio. Prostate. 68:1624–1634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katiyar SK, Roy AM and Baliga MS:
Silymarin induces apoptosis primarily through a p53-dependent
pathway involving Bcl-2/Bax, cytochrome c release, and caspase
activation. Mol Cancer Ther. 4:207–216. 2005.PubMed/NCBI
|
